Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENXBIO Inc. Director's Dealing 2018

Dec 20, 2018

32827_dirs_2018-12-20_9692b6f7-85e4-4bb5-830c-b479f3a47a96.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2018-12-18

Reporting Person: Christmas Patrick J. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-12-18 Common Stock M 5000.00 $12.10 Acquired 7669.00 Direct
2018-12-18 Common Stock S 2225.00 $46.79 Disposed 5444.00 Direct
2018-12-18 Common Stock S 2055.00 $47.85 Disposed 3389.00 Direct
2018-12-18 Common Stock S 720.00 $48.97 Disposed 2669.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-12-18 Employee Stock Option (Right to Buy) $12.10 M 5000.00 Disposed 2026-08-17 Common Stock (5000.00) Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $46.21 to $47.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $47.54 to $48.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $48.77 to $49.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected

F5: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.